{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:29:08Z","timestamp":1782174548153,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005881","name":"Emberi Eroforr\u00e1sok Miniszt\u00e9riuma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis Egyetem","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.pathol.2018.11.007","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T08:53:19Z","timestamp":1546246399000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms"],"prefix":"10.1016","volume":"51","author":[{"given":"R\u00e9ka","family":"M\u00f3zes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrus","family":"G\u00e1ng\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienn","family":"Sul\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"Reiniger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botond","family":"Tim\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Kren\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4609-487X","authenticated-orcid":false,"given":"Hussain","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Ga\u00e1l-Weisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Csomor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Matolcsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Kajt\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-692X","authenticated-orcid":false,"given":"Csaba","family":"B\u00f6d\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2018.11.007_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2018.11.007_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2018.11.007_bib3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A\u00a0unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2018.11.007_bib4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.11.007_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2018.11.007_bib6","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2018.11.007_bib7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.11.007_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.11.007_bib9","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2018.11.007_bib10","first-page":"16","article-title":"Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs)","volume":"2","author":"Luo","year":"2015","journal-title":"Stem Cell Investig"},{"key":"10.1016\/j.pathol.2018.11.007_bib11","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2018.11.007_bib12","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2018.11.007_bib13","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2018.11.007_bib14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2018.11.007_bib15","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2018.11.007_bib16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2018.11.007_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.leukres.2017.12.005","article-title":"Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms","volume":"65","author":"Gango","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.pathol.2018.11.007_bib18","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/leu.2016.45","article-title":"JAK2(V617F) allele burden 50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy","volume":"30","author":"Barosi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2018.11.007_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"Borowczyk","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.pathol.2018.11.007_bib20","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/ajh.24578","article-title":"Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms","volume":"91","author":"Xia","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2018.11.007_bib21","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00277-016-2739-2","article-title":"Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms","volume":"95","author":"Anelli","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pathol.2018.11.007_bib22","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2014.100","article-title":"Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value","volume":"28","author":"Vannucchi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2018.11.007_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.pathol.2016.03.002","article-title":"Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms","volume":"48","author":"Andrici","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2018.11.007_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ajcp\/aqw135","article-title":"CAL2 immunohistochemical staining accurately identifies CALR mutations in myeloproliferative neoplasms","volume":"146","author":"Nomani","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2018.11.007_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/leu.2015.192","article-title":"A\u00a0new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies","volume":"30","author":"Stein","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2018.11.007_bib26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.thromres.2015.07.006","article-title":"The JAK2 V617F mutational status and allele burden \u2013 authors' reply","volume":"136","author":"Borowczyk","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.pathol.2018.11.007_bib27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/leu.2017.150","article-title":"Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era","volume":"31","author":"Falchi","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2018.11.007_bib28","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.leukres.2015.02.006","article-title":"Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations","volume":"39","author":"Li","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.pathol.2018.11.007_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/scd.2017.0137","article-title":"Calreticulin affects hematopoietic stem\/progenitor cell fate by impacting erythroid and megakaryocytic differentiation","volume":"27","author":"Salati","year":"2017","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.pathol.2018.11.007_bib30","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"Andrikovics","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2018.11.007_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cca.2018.05.001","article-title":"Pyrosequencing-based quantitative measurement of CALR mutation allele burdens and their clinical implications in patients with myeloproliferative neoplasms","volume":"483","author":"Oh","year":"2018","journal-title":"Clin Chim Acta"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302518303854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302518303854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:24:53Z","timestamp":1758471893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302518303854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0031302518303854"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2018.11.007","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2018.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}